Published in Cancer Weekly, February 17th, 1997
MedImmune believes that the trial, conducted at the University of Rochester Medical Center, Rochester, New York, represents the first evaluation in humans of a preventative HPV vaccine. There are currently no vaccines to prevent these common sexually transmitted diseases (STDs) that affect 24 to 40 million men and women in the United States. HPVs are responsible for the development of genital warts and cervical cancer.
MedImmune announced on December 11,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.